Table 2 Treatment characteristics of children on first-line and second-line ART at National Pediatric Hospital
First-line | Second-line | p | |||
|---|---|---|---|---|---|
n = 175 | % | n = 57 | % | ||
Clinical status at ART onset | |||||
WHO Stage I | 37 | 21.1 | 5 | 8.8 | 0.06 |
WHO Stage II | 93 | 53.1 | 36 | 63.2 | |
WHO Stage III | 44 | 25.1 | 14 | 24.6 | |
WHO Stage IV | 1 | 0.6 | 2 | 3.5 | |
Initial CD4 cells (%) | 9.1 (3.9–12.9) | 7.9 (2.5–12.8) | 0.1 | ||
Initial CD4 <15 % | 147 | 84.0 | 52 | 91.2 | 0.17 |
Time before ART onset (months) | 2.6 (1.1–15.7) | 2.5 (1.2–8.3) | 0.1 | ||
At the time of survey | |||||
Time on ART (months) | 70.5 (43.9–90.8) | 81.0 (71.4–92.5) | 0.001 | ||
Time since switch on second-line (months) | NA | 36.5 (19.6–55.9) | |||
Time between VL and survey (months) | 0.1 (0.1–4) | 0.1(0.1–4) | 0.7 | ||
Non-adherence to ART | 6 | 3.4 | 0 | 0.1 | |
Weight gain over 1 year (kg) | 3.8 (3.5–4.2) | 3.5 (2.7–4.2) | 0.3 | ||
Last CD4 cells (%) | 27.8 (23.6–31.8) | 22 (19.1–27) | <0.001 | ||
CD4 cells <15 % | 2 | 1.1 | 6 | 10.5 | |
Initial first-line treatment | |||||
3TC + D4T + NVP | 93 | 53.1 | 53 | 93.0 | |
3TC + AZT + NVP | 36 | 20.6 | |||
3TC + D4T + EFV | 30 | 17.1 | 4 | 7.0 | |
3TC + AZT + EFV | 14 | 8.0 | |||
3TC + AZT + LPV | 1 | 0.6 | |||
3TC + D4T + LPV | 1 | 0.6 | |||
Current second-line treatment | |||||
ABC + DDI + LPV | 31 | 54.4 | |||
3TC + TDF + LPV | 13 | 22.8 | |||
3TC + DDI + LPV | 3 | 5.3 | |||
3Tc + AZT + LPV | 3 | 5.3 | |||
ABC + TDF + LPV | 3 | 5.3 | |||
3TC + ABC + LPV | 2 | 3.5 | |||
3TC + AZT + LPV | 2 | 3.5 | |||